Business context and reporting period
The supplied filing is AmpliPhi Biosciences Corporation’s Form 10-K for the fiscal year ended December 31, 2015, filed March 30, 2016. It is not identified as an Armata Pharmaceuticals filing; investors should verify the issuer and period. AmpliPhi was a development-stage biotechnology company developing bacteriophage therapies. Its lead candidate, AB-SA01, targeted Staphylococcus aureus infections; AB-PA01 and AB-CD01 were earlier-stage candidates.
Financial results and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0.475 million | $0.409 million |
| Research and development | $3.992 million | $5.805 million |
| General and administrative | $6.421 million | $6.850 million |
| Operating loss | $10.227 million | $14.110 million |
| Net income (loss) | $(0.516) million | $23.109 million |
| Operating cash used | $9.781 million | $12.572 million |
| Cash and cash equivalents at year-end | $9.370 million | $6.581 million |
Revenue came primarily from legacy gene-therapy sublicensing, not product sales. No product revenue or meaningful operating margin was reported. The 2015 net loss followed a 2014 reported profit largely because of noncash fair-value gains on warrant and Series B preferred-stock derivative liabilities: $9.9 million combined in 2015 versus $37.2 million in 2014. The filing does not identify conventional borrowings as a material balance-sheet item; additional debt financing was cited as a possible future funding source.
At year-end 2015, current assets were $10.016 million and current liabilities were $2.385 million. Total liabilities were $6.889 million; redeemable Series B preferred stock was presented separately. The company raised approximately $13.0 million gross in a March 2015 private placement and reported $12.780 million of net cash from financing activities for the year. Management said existing resources were expected to fund planned operations through the third quarter of 2016.
Material changes versus the prior comparable period
- Revenue increased by $0.066 million, while R&D expense fell by $1.813 million and G&A expense declined by $0.429 million. Operating loss narrowed by $3.883 million.
- Operating cash use decreased by $2.791 million; year-end cash increased by $2.789 million, primarily reflecting the 2015 financing.
- Net results shifted from $23.109 million income in 2014 to a $0.516 million loss in 2015. The comparison is heavily affected by noncash derivative remeasurement gains and should not be read as a change in underlying operating profitability.
- The company restated 2014 and specified 2014–2015 interim-period basic and diluted EPS for errors applying the two-class method and diluted EPS rules. For 2014, basic EPS changed from $5.82 to $4.21 and diluted EPS from a reported $3.37 income per share to a restated loss of $2.33 per share. The company said the restatement did not affect balance sheets, operating loss, net income or cash flows.
Outlook, risks and unusual items
- Management expected R&D expense to rise in 2016 as clinical work, nonclinical studies, hiring and discovery activity advanced. There was no revenue or profitability guidance; the company did not expect product-sale revenue in the near term.
- The company planned AB-SA01 clinical development, including an investigator-sponsored Australian study for chronic rhinosinusitis; the first patient was dosed in January 2016, with data expected in the second half of 2016. It also planned a U.S. Army-supported wound/skin infection trial and anticipated further AB-PA01 development, with a UK clinical-trial application targeted for the first half of 2017.
- The auditor included a going-concern explanatory paragraph, citing recurring operating losses and a net capital deficiency that raised substantial doubt about continued operations. Management depended on raising additional capital; failure to obtain financing could require reductions, delays, asset or rights sales, or a business combination.
- A dispute with principal stockholder Third Security over Series B preferred conversion terms and other charter ambiguities created uncertainty around capitalization and fundraising. Settlement could materially dilute common shareholders; litigation could be costly and have an unfavorable outcome.
- Series B preferred stock accrued cumulative dividends at 10% annually. Accrued unpaid dividends were reported at $3.2 million in risk disclosures; preferred holders could require redemption of all outstanding shares on or after June 26, 2018, subject to the stated terms. The filing also reports $368,000 of dividends payable at year-end to former preferred holders.
- Management identified a material weakness in internal control over financial reporting, including controls over complex and non-routine transactions and EPS accounting; disclosure controls were ineffective. Remediation steps were underway, but completion was not assured.
- Other notable items include $0.289 million of 2015 severance charges, the August 2015 1-for-50 reverse stock split, and a January 2016 Novolytics asset purchase for $146,000 cash plus warrants for up to 170,000 shares.
Important facts for investors to verify
- Confirm that this AmpliPhi 2015 10-K is the intended filing, given the request’s Armata Pharmaceuticals company label.
- Review the full audited statements and notes for the EPS restatement, derivative fair-value accounting, Series B terms and accrued-dividend amounts.
- Assess cash runway and subsequent financing, clinical spending, and whether additional capital was raised after management’s third-quarter 2016 runway estimate.
- Check the status and resolution of the Third Security dispute, preferred-stock conversion/redemption rights, and resulting dilution or cash obligations.
- Confirm progress in remediating the material weakness and whether internal controls and disclosure controls were later judged effective.
- Verify subsequent clinical-trial outcomes and regulatory progress; the filing’s timelines and efficacy statements were forward-looking or based on preclinical/early evidence.